Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
J Clin Microbiol. 2023 May 23;61(5):e0004623. doi: 10.1128/jcm.00046-23. Epub 2023 Apr 27.
Campylobacter ureolyticus is an emerging pathogen increasingly appreciated as a common cause of gastroenteritis and extra-intestinal infections in humans. Outside the setting of gastroenteritis, little work has been done to describe the genomic content and relatedness of the species, especially regarding clinical isolates. We reviewed the epidemiology of clinical C. ureolyticus cultured by our institution over the past 10 years. Fifty-one unique C. ureolyticus isolates were identified between January 2010 and August 2022, mostly originating from abscesses and blood cultures. To clarify the taxonomic relationships between isolates and to attribute specific genes with different clinical manifestations, we sequenced 19 available isolates from a variety of clinical specimen types and conducted a pangenomic analysis with publicly available C. ureolyticus genomes. Digital DNA:DNA hybridization suggested that these C. ureolyticus comprised a species complex of 10 species clusters (SCs) and several subspecies clusters. Although some orthologous genes or gene functions were enriched in isolates found in different SCs and clinical specimens, no association was significant. Nearly a third of the isolates possessed antimicrobial resistance genes, including the resistance gene, potentially conferring resistance to macrolides, the treatment of choice for severe human campylobacteriosis. This work effectively doubles the number of publicly available C. ureolyticus genomes, provides further clarification of taxonomic relationships within this bacterial complex, and identifies target SCs for future analysis.
解脲弯曲杆菌是一种新兴的病原体,越来越被认为是人类肠胃炎和肠道外感染的常见原因。在肠胃炎之外,很少有工作来描述该物种的基因组内容和相关性,特别是关于临床分离株。我们回顾了过去 10 年我们机构培养的临床解脲弯曲杆菌的流行病学。2010 年 1 月至 2022 年 8 月期间共鉴定出 51 株独特的解脲弯曲杆菌分离株,主要来源于脓肿和血培养物。为了阐明分离株之间的分类学关系,并将具有不同临床表现的特定基因归因于分离株,我们对来自各种临床标本类型的 19 个可用分离株进行了测序,并对公共解脲弯曲杆菌基因组进行了泛基因组分析。数字 DNA:DNA 杂交表明,这些解脲弯曲杆菌由 10 个种群聚类 (SC) 和几个亚种聚类组成的种复杂体。尽管一些直系同源基因或基因功能在不同 SC 和临床标本中发现的分离株中富集,但没有一个关联是显著的。近三分之一的分离株具有抗微生物药物耐药基因,包括 耐药基因,这可能赋予对大环内酯类药物的耐药性,大环内酯类药物是治疗人类弯曲杆菌病的首选药物。这项工作有效地将公开解脲弯曲杆菌基因组的数量增加了一倍,进一步阐明了该细菌复合体内部的分类学关系,并确定了未来分析的目标 SC。